Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial

RCT (n=549) found that intra-articular sprifermin 100μg improved femorotibial joint cartilage thickness after 2 years vs placebo, but the difference was of unknown clinical importance. There was no significant difference between 30μg of sprifermin every 6 or 12 months vs placebo.